Lupin exceeded profit expectations in the second quarter, reporting a 74% surge in profits, reaching ₹8.53 billion. This growth was fueled by robust demand for their respiratory and diabetes medications. Overall revenue also saw an 11.3% increase, reaching ₹54.97 billion.
Positive Breakout: These 11 stocks cross above their 200 DMAs
In the Nifty500 pack, 11 stocks’ closing prices crossed above their 200 DMA (Daily Moving Averages) on December 9, 2025, according to stockedge.com’s technical scan